Gene therapy is estimated at 82.0% by therapy type in 2026, with sub-retinal delivery projected at 83.0% and RPGR gene replacement at 58.0%. Adoption depends on genetic confirmation and retinal-center capacity as manufacturing controls restrict broader patient access.
X Linked Retinitis Pigmentosa Market Analysis By End UserX Linked Retinitis Pigmentosa Market Analysis By Route Of AdministrationX Linked Retinitis Pigmentosa Market Analysis By Stage Of DevelopmentX Linked Retinitis Pigmentosa Market Analysis By Treatment ApproachX Linked Retinitis Pigmentosa Market Breakdown By Therapy Type, Stage Of Development, And RegionX Linked Retinitis Pigmentosa Market Opportunity Matrix Growth Vs Value